Skip to main content

Table 3 Changes in sitting systolic blood pressure, sitting diastolic blood pressure and low-density lipoprotein cholesterol at Week 8 from baseline

From: The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia

 

Treatment groups

FMS/RSV vs. FMS

FMS/RSV vs. RSV

 

FMS/RSV

(N = 46)

FMS

(N = 45)

RSV

(N = 44)

LSM difference

(SE)

P-value

LSM difference (SE)

P-value

siSBP

       

  Baseline

152.52 (9.85)

151.33 (8.99)

154.72 (9.46)

    

  Week 8

132.05 (17.45)

134.63 (18.70)

150.21 (17.19)

    

  Change

−20.47 (15.60)

−16.70 (16.54)

−4.50 (15.50)

    

   P-value

<0.001a

<0.001b

0.061a

    

 ANCOVA results

       

  LSM (SE)

−21.89 (2.44)

−19.61 (2.66)

−6.86 (2.71)

−2.28 (3.37)

 

−15.03 (3.39)

 

  (95% C.I.)

(−26.71, −17.07)

(−24.88, −14.35)

(−12.22, −1.50)

(−8.94, 4.39)

0.500d

(−21.75, −8.31)

<0.001d

siDBP

       

  Baseline

89.42 (8.32)

85.78 (9.30)

93.08 (8.46)

    

  Week 8

80.10 (10.47)

79.58 (8.47)

91.73 (11.46)

    

  Change

−9.32 (11.23)

−6.20 (9.98)

−1.35 (9.18)

    

   P-value

<0.001a

0.001a

0.335a

    

 ANCOVA results

       

  LSM (SE)

−10.13 (1.42)

−9.45 (1.59)

−1.18 (1.61)

−0.68 (1.98)

 

−8.95 (2.02)

 

  (95% C.I.)

(−12.94, −7.31)

(−12.60, −6.30)

(−4.37, 2.01)

(−4.60, 3.25)

0.734d

(−12.94, −4.95)

<0.001d

LDL-C

       

  Baseline

171.33 (36.02)

164.09 (39.56)

161.39 (26.71)

    

  Week 8

81.46 (27.10)

154.40 (52.37)

77.25 (23.33)

    

  Percentage change

−52.36 (12.97)

−6.52 (20.48)

−51.52 (15.80)

    

   P-value

<0.001b

0.112c

<0.001c

    

 ANCOVA results

       

 LSM (SE)

−52.74 (2.57)

−5.83 (2.77)

−50.92 (2.83)

−46.91 (3.53)

 

−1.82 (3.57)

 

 (95% C.I.)

(−57.82, −47.66)

(−11.31, −0.35)

(−56.52, −45.31)

(−53.89, −39.92)

<0.001d

(−8.89, 5.24)

0.611d

  1. FMS/RSV fimasartan 120 mg/rosuvastatin 20 mg treatment, FMS fimasartan 120 mg alone treatment, RSV rosuvastatin 20 mg alone treatment, LDL-C low-density lipoprotein, siSBP sitting systolic blood pressure, siDBP sitting diastolic blood pressure, SD standard deviation, LSM least square mean, SE standard error, ANCOVA analysis of covariance
  2. Percent change from baseline was compared by apaired t-test, bone sample t-test, or cWilcoxon signed rank test
  3. dComparison between the combination therapy and monotherapy was analyzed by ANCOVA model adjusted for baseline values, age, gender and smoking status